Medprin

Medprin biotech is a high-tech enterprise co-founded by outstanding biomedical scientists in September 2008. The company specializes in research and development, production, and sales of regenerative medicine materials and regenerative implantable medical devices. Medprin aims to become a global leader in the field of implantable medical devices by leveraging its expertise in biological 3D printing technology and nano-bionics technology.

Medprin's flagship product, ReDura Biomimetic-Synthetic-Absorbable Dural Substitute, received CE and CFDA registration certification. As of 2020, ReDura has been used in over 30 countries across tens of thousands of cases, positioning it as a dural substitute with the closest resemblance to a patient's autologous cells and the best repair effect. The company has established branches in the US, Germany, and China to support its global market expansion efforts.

In addition to ReDura, Medprin is developing a range of human tissue repair products, including personalized skull and maxillofacial repair systems, female pelvic diaphragm repair systems, tensionless urethral slings, hernia repair pieces, artificial skin, blood vessels, and ligaments. These products lay the foundation for the future development of more complex and advanced artificial tissues and organs.

Medprin places a strong emphasis on intellectual property protection, having applied for 52 domestic and foreign patents, with 28 patents granted in the US, Russia, China, and other countries as of 2020. The company's commitment to continuous innovation aims to establish it as the world's leading high-end implantable medical device company, contributing significantly to the improvement of Chinese technology and the industrialization of medical devices.